Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v5-FR
Language French French
Date Updated 2020-09-15 2020-09-15
Drug Identification Number 02256711 02256711
Brand name RANITIDINE INJECTION USP RANITIDINE INJECTION USP
Common or Proper name RANITIDINE RANITIDINE
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients RANITIDINE RANITIDINE
Strength(s) 50MG 50MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 50ML 50ML
ATC code A02BA A02BA
ATC description DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date 2020-09-14 2020-09-14
Actual start date
Estimated end date Unknown 2020-09-28
Actual end date
Shortage status Actual shortage Actual shortage
Company comments
Health Canada comments